Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 59HER2-positive Breast Cancer 14Carcinoma, Non-Small-Cell Lung 5Breast Diseases 4Brain Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2HER2-positive Metastatic Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Invasive 2Breast Cancer Female 2Advanced Breast Cancer 2Stomach Neoplasms 1Solid Tumor 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1HER-2 Positive Colorectal Cancer 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1

Interventions

Capecitabine 6Irinotecan 5Fluorouracil 5Cisplatin 5Oxaliplatin 4Leucovorin 4Gemcitabine 4apatinib 3Sorafenib 3Bevacizumab 3tislelizumab 2pembrolizumab 2Sunitinib 2Radiotherapy 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cyclophosphamide 2Cetuximab 2Aspirin 2Ascorbic Acid 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1lutetium Lu 177 dotatate 1huachansu 1halofantrine 1guadecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Digestive System Neoplasms × pyrotinib × Clear all
NCT04960943 2021-07-14

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Fudan University

Phase 2 Unknown
60 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡